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Background: Articular cartilage, because of its avascular nature, has little capacity for spontaneous healing, and
tissue engineering approaches, employing different biomaterials and cells, are under development. Among the
investigated biomaterials are the chitosan-based hydrogels. Although thoroughly studied in other mammalian
species, studies are scarce in equines. So, the aim of the present study was to investigate the biocompatibility of
chitosan-GP in horse joints submitted to high mechanical loads.
Results: An osteochondral defect was created by arthroscopy in the medial surface of lateral trochlea of talus of
left or right leg, randomly selected, from six healthy geldings. The defect was filled up with chitosan-GP. The
contralateral joint received an identical defect with no implant. The chondral fragment removed to produce the
defect was collected, processed and used as the “Initial” sample (normal cartilage) for histology, immunohistochemistry,
and metabolic labelling of PGs. After 180 days, the repair tissues were collected, and also analyzed. At the end of
the experiment (180 days after lesion), the total number of cells per field in repair tissues was equal to control,
and macrophages and polymorphonuclear cells were not detected, suggesting that no significant inflammation
was present. These cells were able to synthesize type II collagen and proteoglycans (PGs). Nevertheless, the cell
population in these tissues, both in presence of chitosan-GP and in untreated controls, were heterogeneous, with
a lower proportion of type II collagen-positives cells and some with a fibroblastic aspect. Moreover, the PGs
synthesized in repair tissues formed in presence or absence of chitosan-GP were similar to those of normal
cartilage. However, the chitosan-GP treated tissue had an disorganized appearance, and blood vessels were present.
Conclusions: Implanted chitosan-GP did not evoke an important inflammatory reaction, and permitted cell growth.
These cells were able to synthesize type II collagen and PGs similar to those synthesized in normal cartilage and in
healing tissue without implant, indicating its chondrocyte nature.
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Injuries to articular cartilage are common, and may cause
pain, disability, impairment, and early retirement of
athletes. Once damaged, articular cartilage has very little
capacity for spontaneous healing, and many repair tech-
niques have been proposed over the last decades. How-
ever, repair of articular cartilage by traditional methods is
challenging, due to its avascular nature and lack of a sig-
nificant population of progenitor cells. For this reason,* Correspondence: yara.bioq@epm.br
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reproduction in any medium, provided the ortissue engineering approaches, employing cells to in situ
regenerate articular cartilage, are under development [1-3].
Both fully differentiated chondrocytes and progenitor
cells (mesenchymal stem cells) have been used to pro-
duce hyaline-like cartilage [4,5]. Nevertheless, the strat-
egies of cell implantation within the joint also poses
challenges: a fluid environment, strong shear forces,
mechanical loads, and stiff, irregular and often bleeding
surfaces not easily amenable to insertion of biomaterials.
Furthermore, the biomaterials to be used as cell-delivery
vehicles must meet stringent requirements in that the
material should be non-toxic, non-immunogenic, and
must either integrate with the repair tissue or degradeLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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debris or fissures in the tissue [6]. The ideal scaffold
should mimic the naturally occurring environment in
the articular cartilage extracellular matrix (ECM), allow-
ing chondrocyte proliferation and synthesis of cartilage
ECM, which is composed by a dense network of collagen
fibers [7], proteoglycans (PGs), and other proteins [8].
PGs are composed by a protein core with glycosamino-
glycan (GAG) side chains. GAGs, in turn, are heteropoly-
saccharides constituted by repeating disaccharide units
formed by a hexosamine (glucosamine or galactosamine)
and a non-nitrogen monosaccharide (uronic acid or gal-
actose). Most GAGs are sulfated in different degrees and
positions, and both the carboxyl and the sulfate groups
contribute to its polyanionic nature. The main cartilage
matrix PG is aggrecan, a high molecular weight PG of the
hyalectan family, composed by a ~200 kDa core protein
substituted with ~100 chondroitin sulfate and ~30 keratan
sulfate side chains. Aggrecan interacts with hyaluronic
acid, forming large aggregates, which are entrapped in the
collagen network, and provide cartilage its osmotic prop-
erties, giving cartilage its ability to resist compressive loads
review in [9]. Other PGs, such as decorin, biglycan and
fibromodulin, which are characterized by their ability to
interact with collagen, are also present. They are much
smaller than aggrecan, but may be present in similar
molar amounts.
The structure and composition of aggrecan in articular
cartilage changes when growth and calcification pro-
cesses occur in the tissue, both during normal develop-
ment and in diseases such as osteoarthritis and tumors
[10,11]. Furthermore, the extracellular matrix compos-
ition, the cell density [12], and even mechanical com-
pression [13] affect the chondrocyte phenotype and the
synthesis of ECM components. Thus, the composition of
any biomaterial used as in cartilage regeneration proce-
dures is very important.
A wide array of matrices or hydrogels have been used
as biomaterials, including proteins (collagen and fibrin),
polysaccharides (agarose, alginate, hyaluronic acid and
chitosan), and polymers (polyethylene glycol, poly-lactic
acid) [7]. Chitosan-based hydrogels are promising due to
their structural analogy to GAGs.
Chitosan is a partially deacetylated derivative of chitin,
isolated from arthropod exoskeleton [14]. It is a linear
polysaccharide consisting of β (1–4) linked D-glucosamine
residues, with a variable number of randomly located
N-acetyl-glucosamine residues. Chitosan is a semi-
crystalline polymer, and the degree of crystallinity is a
function of the deacetylation level. Because of its struc-
ture, chitosan is normally insoluble in aqueous solutions
above pH 7, but, in dilute acids, the free amino groups
are protonated and the molecule becomes fully soluble
below pH 5 [15].Many chemical derivatizations of chitosan have been
used to promote new biological activities and to modify its
mechanical properties [16,17]. The addition of polyol salts
such as sodium glycerol phosphate to chitosan creates
chitosan-glycerol phosphate (GP), a thermosensitive hydro-
gel that forms a viscous liquid at room temperature or
below, and converts to a semisolid gel at body temperature
[18-20]. Chitosan-based vehicle can be loaded into an
osteochondral defect in living joints as a viscous liquid, and
upon solidification, adheres to bone and to cartilage [15].
Furthermore, previous studies have shown that chitosan is
hemostatic [21], and stimulates revascularization of the
wound and connective tissue repair [22].
The aim of the present study was to investigate the
biocompatibility of a chitosan-based hydrogel – chitosan-
GP – in horses, specifically in joints submitted to high
mechanical load. If proved biocompatible in horses,
chitosan-GP could be used, in the future, as a vehicle
for cell and/or drug delivery as an adjuvant to promote
cartilage regeneration.
Methods
Animals
The present work was approved by the Ethical Committee
of Universidade de São Paulo – USP (1245/2007), and was
carried out in accordance with USP guidelines, and also
in accordance with EC Directive 86/609/EEC for animal
experiments http://ec.europa.eu/environment/chemicals/lab_
animals/legislation_en.htm.
Six Mangalarga healthy geldings, 3 years old, 300–
315 kg body weight (average = 307 kg), from the USP re-
search herd, were used in the present study. Clinical,
laboratorial, radiographic and ultrassonographic exams
were performed before inclusion in the experimental
group, and all were considered normal. The animals
were housed in single 12 m2 boxes (3 × 4 m) and fed pel-
lets (1% of the animal body weight), coast cross hay and
water ad libitum.
Preparation and application of chitosan-glycerol
phosphate gel
Chitosan-GP gel was obtained as described by Chenite
et al. [18]. In brief, chitosana of 310–375 kDa (based on
the viscosity range of 800–2000 mPaS) deacetylation
grade >75% (200 mg), was solubilised in 0.1 M hydro-
chloric acid (9 mL). To this solution, 560 mg of sodium
glycerol phosphateb dissolved in 1 mL of water were
added, slowly and under continuous agitation. A whitish
gel resulted, which was transferred to glass tubes, steril-
ized in autoclave, and stored for no more than 24 h at
room temperature.
To test the biocompatibility of chitosan-GP, an osteo-
chondral defect (1 cm diameter and 0.5 cm deep) was
created by arthroscopy in the medial surface of lateral
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A cartilage sample was collected with Ferris-Smith ron-
geous, and used as “Initial sample”. Afterwards, a de-
pression was created in the subjacent bone using a bone
burr attached to a power shaving system. This osteo-
chondral defect was filled up with chitosan-GP gel
(~0.5 mL). The gel was delivered using an insulin syr-
inge (1 mL), with cut end. For gel delivery, fluid infusion
was replaced by CO2, using a laparoscopic insuflattor
calibrated to maintain 30 mmHg until the end of the
procedure, allowing gel retention in the defect. The
contralateral joint received an identical defect with no
implant, and served as matched control.
After arthroscopy, all horses received intravenous ami-
kacin, 15 mg/kg, and phenylbutazone, 4.4 mg/kg, every
24 h, for three days. At the end of the experimental
period (day 180), arthroscopy was repeated for the col-
lection of the “Final” samples, and the same antibiotic
and anti-inflammatory therapy was repeated.
Cartilage analysis
The cartilage samples collected during arthroscopy were
cut in three fragments, used for: (1) histology; (2) immu-
nohistochemistry for type II collagen; (3) metabolic la-
belling and analysis of proteoglycans (PGs).
Histology
For histology, the tissue fragments were fixed in Metha-
carn (60% methanol, 30% chloroform, 10% acetic acid)
for 6 h, and then transferred to 90% ethanol. The tissues
were dehydrated, embedded in paraffin, and cut in 3 μm
sections. These sections were transferred to silane-
coated microscope slides, dewaxed and stained with
hematoxylin and eosin (H & E).
Immunofluorescence of type II collagen
For immunofluorescence labelling, the tissue fragments
were fixed as above described, dehydrated, embedded in
paraffin, and cut in 5 μm sections. These sections were
transferred to silane-coated microscope slides and
dewaxed. Antigen retrieval was performed by incubation
with 0.4% pepsin (Sigma) in 0.5 M acetic acid, 30 min,
37°C. After washing with phosphate buffering saline
(PBS), polyclonal anti-type II collagen antibodyc was
added as primary antibody (100 μL), 1:50 in blocking so-
lution containing 1% bovine serum albumin, BSAd, 0.3%
Tween 20 and 0.1% sodium azide. This antibody binds
both type II mature collagen and procollagen. After
overnight incubation at 4°C, the slides were washed with
PBS and incubated with secondary antibody swine anti-
rabbit IgG, FITC-conjugatede, diluted 1:100 in PBS.
After 90 min incubation in moist and dark chamber,
the sections were counterstained with propidium iodide
(1:1000), which stains cell nucleus in red. Slides weremounted in Vectashield to preserve fluorescencef, and
sealed with clear nail polish. Negative controls consisted
of cartilage sections that had not been incubated with
primary antibody.
Images were obtained with a Nikon E-800 fluorescence
microscope, 400 times magnification, and morphometric
analysis was performed using the software Image Pro-
Plus 4.5. The evaluation consisted of counting 100 cells
per sample, in random selected fields, following basic
stereological principles. The results are expressed in per-
centage of type II collagen -positive cells.
Metabolic labelling and analysis of proteoglycans
For metabolic labelling of PGs, the cartilage fragment
(~100 mg) was transferred to a sterile bottle containing
10 mL of F12 culture medium containing penicillin
(10.000 U), streptomycin (100 mg) and 35S-sulfateg
(100 μCi). The tissue explants were transferred to Dept.
of Biochemistry, Escola Paulista de Medicina, and main-
tained at 37°C in a 2.5% CO2 atmosphere. After 24 h,
the medium and the tissue explants were collected and
processed separately.
Extraction of 35S-PGs from tissue explants
From the conditioned culture medium, the PGs were
precipitated by careful and slow addition of methanol
(3 volumes), and after 18 h at −20°C, the precipitate
formed was collected by centrifugation, dried and resus-
pended in 100 μL of water for analysis.
From the tissue explants, 35S-PG extraction was per-
formed as previously described [23-25]. Each tissue ex-
plant was carefully cut in small pieces, and incubated with
1 mL of 4 M guanidine hydrochloride (GuHCl)h in 0.05 M
sodium acetate buffer, pH 6.5, containing protease inhibi-
tors (0.1 M є-aminocaproic acid, 6.5 mM benzamidine,
5.5 mM iodocetamide and 0.1 M phenylmethylsulfonyl
fluoride). After overnight incubation at 4°C under agita-
tion, debris was collected by centrifugation, and the ex-
traction process was repeated with 0.5 mL of the 4 M
GuHCl. After 24 h, debris was removed by centrifugation
and both supernatants were combined. PGs were precipi-
tated by slow addition of methanol (3 volumes), under agi-
tation. Subsequently, the precipitates formed after 18 h
at −20°C were collected by centrifugation (3000 × g,
20 min), washed with 80% methanol, and vacuum dried.
The dried material was resuspended in water (100 μL),
and the solutions were stored at −20°C.
Identification and quantification of 35S-PGs
The 35S-PG samples were analyzed by a combination of
agarose gel electrophoresis and enzymatic degradation
with proteases and specific GAG lyases, as already de-
scribed [26]. Aliquots of the 35S-PG-containing solutions
(5 μl containing 0.5-5 μg) were submitted to agarose gel
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buffer (PDA), pH 9 [27]. After fixation with cetyltri-
methylammonium bromide and Toluidine Blue staining,
PGs were quantified by densitometry of the gel slabsi.
The 35S-sulfate labelled compounds were visualized
by exposure of the gel slabs to a Packard Cyclone TM
Storage Phosphor System by 24 hours. For quantifica-
tion, the bands containing radiolabelled compounds
were scrapped from the gel slabs and counted in a liquid
scintillation spectrophotometer, using Ultima Gold LSC-
Cocktailj. The quantitative results were always corrected
for 35S-decay.
Statistical analysis
Data were evaluated for normality by the Kolmogorov-
Smirnov test. Afterwards, the Analysis of Variance was
used to compare the groups and effect of treatments. To
contrast between mean values the Tukey-Kramer test
was used. For non-parametric values, Kruskal-Wallis test
was used to compare initial and final results, while
Mann–Whitney test was used to compare the chitosan-
GP-treated joints to the untreated. The GraphPad Instat
3 was used to perform the statistical analysis.
Results
Histology and immunohistochemistry of type II collagen
with fluorescence labelling
Gross observation revealed that at the beginning of ex-
periment, the articular cartilage was normal with smooth
surface. At the end of experimental period (day 180), a
slight depression was easily detected by arthroscopy as
the lesion was observed. The surface was also smooth
and cartilage-like. Histological images of the initial chon-
dral fragment obtained by arthroscopy is shown in
Figure 1 (A and B). Chondrocytes are embedded in
abundant avascular ECM of homogeneous appearance
upon HE staining. Figure 1-C shows that, 180 days after
osteochondral injury (Final), the chitosan-GP treated tis-
sue had an abnormal, disorganized appearance. The cells
were also embedded in abundant ECM, but now blood
vessels were present. In both healing tissues, some cells
presented a “fibroblastic” morphology. Possibly, they are
mesenchymal cells that could differenciate into either
chondrocytes or fibroblasts. The total number of cells
per field did not change, and macrophages and poly-
morphonuclear cells were not detected, suggesting that
no significant inflammation was present in the “Final”
samples (180 days). Similar results were obtained for all
animals, and Figure 1 shows representative samples of
each group.
Immunofluorescence for type II collagen was per-
formed as described in Methods, and the percentage of
type II collagen-positive cells was measured (Figure 2).
Although the matrix was also labelled, our focus was thenewly synthesized pro-collagen present in the cells. In
normal cartilage, about 70% of the cartilage cells were
type II collagen-positive, while in healing tissues this
number was much lower (~40%). Nevertheless, there
was no difference between healing tissues formed in
presence or absence of chitosan-GP.
Proteoglycans
Representative agarose gel electrophoresis of 35S-PG ex-
tracted from cartilage explants (T) and conditioned cul-
ture medium (M), from normal tissues obtained at the
beginning of experiment (Initial), and repair tissues col-
lected at the end of experimental period (Final), from
chitosan-GP-treated lesions (Chitosan-GP) and un-
treated lesions (No treatment) is shown in Figure 3. Both
Toluidine Blue staining and radioautograms are shown.
The radioactive band corresponded to the Toluidine
Blue stained PGs, indicating that PGs were the main
35S-sulfate labelled compounds. Intact PGs migrated
near heparan sulfate (free GAG), but upon digestion
with proteases (not shown), only chondroitin sulfate free
chains appeared, indication that most of the 35S-PGs
synthesized are chondroitin sulfate-PGs.
Figure 4 shows the quantitative data for total PGs
(stained by Toluidine Blue and quantified by densitom-
etry) and newly synthesized, labelled PGs (35S-PGs). In
all cases, most of the 35S-PGs were found in the tissue
explants, with only 10-12% of total 35S-PGs in culture
medium of normal tissues (Initial). Although both
the total amounts of PGs (Figure 4-A) and 35S-PGs
(Figure 4-B) were lower in healing tissues, a higher pro-
portion (30-33%) was found in culture media (Figure 4-C),
suggesting that the extracellular matrix was less dense than
in the normal tissue. The healing tissues contained also
lower amounts of PGs, detected both by Toluidine Blue
staining and radioactivity.
The PG concentration in the culture medium was very
low, undetectable by Toluidine Blue staining. For this rea-
son, it was impossible to determine the specific activities
of PGs secreted to the culture medium. So, only tissue
explants were considered to measure specific activities.
In healing tissues, although the amounts of PGs were
lower than normal, the specific activities were increased
(Figure 5), indicating higher synthesis rates. The specific
activities were even higher in the chitosan-GP-treated
lesions. Nevertheless, individual variation did occur, pos-
sibly due to different numbers of PG-synthesizing cells in
each sample.
Discussion
Much of the potential of chitosan as a biomaterial is
thought to come from its cationic nature and high charge
density. Because the chitosan charge density is pH-
dependent, transfer of chitosan-polyanion complexes to
Figure 1 Optical microscopy of normal articular cartilage (A and B, Initial) collected at the first arthroscopy to produce the
osteochondral defect, and the healing tissues (Final, day 180) formed in presence (C) or absence of chitosan-GP (D). Tissue samples
collected during surgery were fixed in Methacarn, transferred to 90% ethanol, dehydrated, embedded in paraffin and cut in 3 μm sections.
These sections were transferred to silane-coated slides, dewaxed, and stained with hematoxylin and eosin (H & E).
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lized polyanion, and this could be used for local delivery
of biologically active molecules [28]. Furthermore, the N-
acetylglucosamine moiety of chitosan is also found in
some GAGs, such as hyaluronic acid, heparan suphate
and heparin, giving these molecules a certain degree of
structural analogy. It is possible that chitosan might
present some of the GAG biological activities, such as theFigure 2 Percentage of cells stained for type II collagen in
normal articular cartilage (Initial) and in healing tissues formed
in presence or absence of chitosan-GP. Cells were counted under
fluorescence microscope, and the relative number of type II
collagen-positive cells (green and yellow cells) is given (as percent).
Brackets indicate differences statistically significant (P < 0.05).ability to bind growth factors, receptors and adhesion
molecules. However, Hamilton et al. claim that other
properties may be important in biological performance of
chitosan [29].
Many authors propose chitosan-based biomaterials for
cartilage tissue regeneration, but different chitosan for-
mulations are used. The chitosan molecular weight may
range from as little as 10 kDa to over 1,000 kDa, while
the deacetylation degree may oscillate from 50% to 95%
[30]. High molecular weight and high deacetylation de-
grees are related to lower material degradation, while
the deacetylation degree is also related with cell adhe-
sion and proliferation. In the present paper, we choose
to employ an intermediate molecular weight, and a 310–
375 kDa chitosan, with 75% deacetylation was used.
The chitosan primary amino groups are reactive and
provide a mechanism for side group attachment using
mild reaction conditions. The general effect of addition of
a side group is to disrupt the crystalline structure of chi-
tosan and hence increase the amorphous fraction, gen-
erating a material with lower stiffness and altered
solubility. Chitosan-GP is one such compound [19], hav-
ing the additional benefit of forming a thermosensitive
hydrogel that forms a viscous liquid at room temperature,
and converts to a semisolid gel at body temperature, mak-
ing easier its application in osteochondral defects. There
Figure 3 Agarose gel electrophoresis of 35S-PGs from normal
articular cartilage (Initial) and healing tissue (Final, 180 days)
formed either in absence (No treatment) or in presence of
chitosan-GP. Normal articular cartilage samples collected during the
first arthroscopy to produce the osteochondral defect (~100 mg,
wet weight), as well as samples of the healing tissues formed in
presence or absence of chitosan-GP, were metabolically labeled with
35S-sulfate. 35S-PGs were isolated from the conditioned media (M)
and the tissue explants (T). These compounds were analyzed by
agarose gel electrophoresis (PDA buffer), and localized in the gel by
Toluidine Blue staining (left) and radioautography (right).
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system induced by heating is the result of a progressive
and homogeneous reduction of the ionization degree of
chitosan [31].
Other carbohydrate-based biomaterials, such as poly-
lactic/polyglycolic acids, agarose, and alginate, have been
used, but most of them, in contrast to chitosan, give
strong foreign body reactions review in [32].
Although thoroughly studied in humans and in experi-
mental models reviews in [1,14], only a few reports onthe use of chitosan-based biomaterials in equines have
been published [33], and while the body response to
various chitosan-based implants has been studied in
other species [30,34], there are scarce studies in horses.
In general, studies in other species have revealed that
chitosan-based materials are biocompatible and evoke
minimal foreign body reaction. Chitosan, chitosan frag-
ments, and chitin have been shown to have short-term
stimulatory effects on the immune system [35-37], which
may play a role in inducing local cell proliferation and
ultimately integration of the implanted material within
the host tissues. In the rabbit, it was shown that less
adverse tissue response occurred with better biodegrad-
able samples, of low molecular weight chitosan and low
deacetylation degree (83%) [30]. With high molecular
weight chitosan (350–510 kDa) or high deacetylation de-
gree (91%), however, Abarrategi et al. described synovial
membrane inflammation, no cartilage formation, no ma-
terial degradation, and nonsmooth surface [30]. In con-
trast, our findings in horses, using chitosan-GP of 310–
375 kDa and 75% deacetylation, revealed smooth surface,
with a good host integration of healing tissue, and no
evidence of chronic inflammation in any of our experi-
mental animals. Blood vessels were observed in repair tis-
sues formed in presence of chitosan-GP, as were also
reported by others, who concluded that chitosan induces
a transient vascularization when implanted in cartilage
[30]. In a rabbit model, chitosan-GP/blood implants in-
duce angiogenesis and subchondral bone remodeling.
These observations suggest that chitosan-GP/blood im-
plants leads to a porous subchondral bone structure with
well vascularized marrow cavities, that could promote
more effective cartilage repair [38].
Histology of the repair tissue did not show any changes
in the number of cells per field, and macrophages and
polymorphonuclear cells were not detected, indicating that
the implanted chitosan-GP did not evoke an important
inflammatory reaction, while permitting cell proliferation.
These cells were able to synthesize type II collagen and
PGs, suggesting its “chondrocyte” nature. Nevertheless, the
cell population in healing tissues, both in presence of
chitosan-GP and in untreated controls, were heteroge-
neous: only ~40% of the cells were type II collagen-
positives and some presented a fibroblastic aspect under
light microscopy. A histological scoring system, as well as
staining with Safranin-O, Toluidine Blue, and use of polar-
ized microscopy for collagen could be useful to further
characterize the healing tissues. However, tissue fragments
were differently processed for histology, immunofluores-
cence, and proteoglycan synthesis under tissue culture
conditions, leaving not enough material left for the above
mentioned analyses.
Moreover, the PGs synthesized in presence of chitosan-GP
were similar to those synthesized in healing tissue without
Figure 4 Total and 35S-PGs from normal articular cartilage (Initial) and healing tissue (Final) formed in presence or absence of
chitosan-GP. The experiment was performed as described in Figure 4, except that quantitative data are shown for total PGs (A), quantified by
densitometry of the Toluidine Blue-stained agarose gel electrophoresis, and 35S-PGs, quantified by the radioactivity of the 35S- containing bands
(B). Mean ± standard error is shown in (A) and (B), while (C) shows the distribution of 35S-PGs in culture medium and tissue explants.
Figure 5 Individual and mean 35S-PGs specific activities from normal articular cartilage (Initial) and healing tissue (Final) formed in
presence or absence of chitosan-GP. The experiment was performed as described in Figure 3, except that only the PGs extracted from tissue
explants were considered. Specific activity is expressed as cpm/μg of tissue protein. Individual paired results, and mean ± standard error are
shown in (A) and (B), respectively.
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proportions of PGs were found in the culture medium of
repair tissues. This suggests that the extracellular matrix
of the newly synthesized tissue is less dense, in agreement
with the findings on type II collagen labelling (see Figures 2
and 4). Chitosan-GP in horses did not increase the PG
synthesis rate, although the specific activity of 35S-PGs
was slightly increased (difference not statistically signifi-
cant, Figure 5). This is also in agreement with previously
reported data on chondrocytes cultured on chitosan-
chondroitin sulphate complexes [14], which produced
equal to control amounts of PGs and type II collagen.
Nevertheless, the specific activity of 35S-PGs varied among
different animals. This is possibly due to the variations in
the number of PG-synthesizing cells in each sample.
It is worth mentioning that these results are related to
the osteochondral defect model here employed. In the
equine species, the relevance of this model resides in the
high prevalence of osteochondral lesions, both acquired
or inherited [39,40]. Furthermore, the choice of the
depth of the articular cartilage defect has great impact in
the tissue response. Osteochondral defects, as employed
in the present study, span the entire depth of articular
cartilage and penetrate subchondral bone marrow, creat-
ing an access to blood cells, macrophages, mesenchymal
cells and soluble factors [41]. Osteochondral defects ex-
hibited a rapid cellular response, as opposed to chondral
defects, which exhibited a minor healing response, with
little cell infiltrates [42]. It is also important to mention
that both models of defect design – chondral and osteo-
chondral – are relevant for equines [43,44] as well as for
other species [32,41], and the choice to use one or the
other must be made judiciously.
Conclusions
Despite extensive research on articular cartilage healing
during the last decades, successful repair of damaged
cartilage has not been fully achieved. While many new
techniques have recently emerged and demonstrated
promising results in experimental models, few have ex-
hibited long-term clinical efficacy. Tissue engineering
has recently emerged as an interdisciplinary topic, using
in vitro cultured cells and tissues, together with artificial
implants. Our findings on chitosan-GP suggest that it
may be well suitable as a biomaterial for cartilage repair
[45] that could also be used in drug and/or cell delivery
[46]. Future studies using in vitro cultured chondrocytes
will explore this potential.
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